查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197721

神经康復设备市场-增长、趋势、COVID-19 影响和预测 (2023-2028)

Neurorehabilitation Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

神经康復设备市场预计在预测期内（2022 年至 2027 年）的复合年增长率为 13.7%。

COVID-19 对神经康復设备市场的增长产生了重大影响。 例如，根据 2021 年 10 月发表的题为“COVID-19 大流行期间的远程神经康復：对中低收入国家 (LMIC) 实践的启示”的研究，远程康復可以帮助对抗大流行情况。但是，它有被认为是一项重要的创新和减少全球残疾的有效战略。 我们还报告说，大流行情景提供了一个机会来优化和扩大与医学相关的技术进步，以解决 LMIC 中日益增加的神经系统疾病负担。 因此，COVID-19 对市场增长产生了显着影响。

神经康復设备有助于改善功能、减轻症状并改善外伤、神经系统疾病和其他疾病患者的健康状况。 2020 年 2 月发表的一项题为“年轻人缺血性中风：全球视角”的研究发现，全世界每年大约发生 1100 万例缺血性中风，其中一半以上是中低规模的。我们知道它发生在收入国家。 缺血性中风是导致长期残疾的主要原因，对患者和护理人员的生活质量有重大影响。 缺血性中风日益增加的负担正在推动市场的增长，因为神经康復设备用于大约 40% 的缺血性中风病例并且可以改善神经功能。

此外，随着老年人更容易患急性脑梗塞、阿尔茨海默病和帕金森病等各种神经系统疾病，老龄化速度的加快也推动了市场增长。 例如，根据联合国公布的《2020年世界人口老龄化亮点》，2020年世界老年人口（65岁及以上）将达到7.27亿，预计到2050年底将达到15亿。我在这。 因此，预计世界上不断增加的老年人口将产生对更多神经康復设备的需求，这将对所研究市场的增长产生重大影响。

此外，国际监管机构对神经康復设备的批准也有助于预测期内的市场增长。 例如，2021 年 4 月，美国食品和药物管理局推出了 IpsiHand 上肢康復系统（IpsiHand System），这是一种脑机接口（BCI）设备，用于帮助中风患者康復上肢或手、腕部残疾，或武器。授予授权。

因此，神经系统疾病患病率上升、老年人口增加以及神经康復设备技术进步是市场增长的主要驱动力。 然而，神经康復设备的高成本可能会阻碍预测期内的市场增长。

神经康復设备的市场趋势

在神经康復设备市场，神经机器人设备领域有望占据主要市场份额

神经机器人设备细分市场预计神经康復设备市场将出现显着增长。 神经系统疾病负担的增加、机器人技术的进步、与神经科学的融合以及新产品的发布预计在预测期内将显示出类似的趋势。

神经机器人设备结合了神经科学和康復，是一种治疗神经系统疾病的新方法，可根据您想要恢復的特定功能提供不同的治疗方法。 用于神经康復的机器人设备可大致分为两类，例如末端执行器设备和外骨骼，具体取决于人与机器人之间的物理交互类型。

为了解机器人方法在神经康復中的有效性而进行的研究也将有助于这些设备的采用，从而推动这一领域的发展。 例如，在 2020 年 5 月发表的题为“小儿神经康復中的机器人技术”的研究中，在意大利一家儿科医院进行的人为因素试点研究中，在使用机器人进行神经康復治疗后，患者报告说生活质量和满意度有所提高。 接受机器人治疗的患者父母也报告了比接受常规治疗的患者略高的期望和满意度。 还表明，机器人神经康復方法显着提高了患者和家长的期望。 因此，神经机器人设备在各种研究中的高效能可能会增加对这些设备的采用并刺激该领域的发展。

此外，新成立的机器人辅助神经康復中心提高了神经机器人设备的可及性，预计这将有助于该细分市场的增长。 例如，2021 年 12 月，领先的医疗机构之一撒克拉世界医院 (Sakra World Hospital) 在印度卡纳塔克邦推出了世界一流的机器人辅助神经康復中心。

因此，神经系统疾病患病率上升、与神经机器人设备相关的好处、机器人辅助神经康復中心的建立以及技术进步是神经机器人设备领域的主要驱动因素。.

北美将占据很大的市场份额，预计在预测期内也会如此

由于中风、阿尔茨海默病、帕金森病发病率上升、老年人口增加以及该地区神经康復设备技术的进步，预计北美将在全球神经康復设备市场占据重要市场份额。

根据美国疾病控制和预防中心 2022 年 5 月的更新，每年大约有 795,000 人经历新发或复发中风。 流行病学数据显示，美国大约 87% 的中风是缺血性中风。 缺血性中风的增加将导致该地区神经康復设备的采用增加，从而推动北美同一市场的增长。

主要参与者旨在提高对神经康復的认识和采用的举措越来越多，预计将在预测期内进一步推动美国这一市场的增长。 例如，2021 年 9 月，Evolution Devices 启动了 EvoWalk 平台试点项目，为神经性部分步态麻痹患者提供步态康復服务。 该公司的方法将远程物理治疗 (PT) 与其 EvoWalk 智能刺激设备相结合，以帮助患者避免跌倒并恢復本能运动。

此外，2021年12月，国际非营利社区组织老鹰兄弟会（F.O.E）内布拉斯加州分部将代表当地内布拉斯加州住院康復机构提供EksoNR设备。你说你买了两个。 因此，越来越多地采用这些神经康復设备也促进了市场增长。

此外，对神经康復设备好处的认识不断提高以及成熟的医疗基础设施的存在也显着推动了该地区的市场增长。

神经康復器械市场竞争者分析

神经康復设备市场是整合的，由几家主要参与者组成。 从市场份额的角度来看，一些主要参与者主导着市场。 目前主导市场的公司有 Hocoma AG、Bionik Labs、St. Jude Medical Inc.（Abbott Laboratories）、Electron Ltd、MagVenture A/S、Helius Medical Technologies、Ekso Bionics、Rehabtronics Inc 和 Rehab-Robotics Company. Limited， ETC。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 神经系统疾病患病率上升
    • 神经康復设备技术进步
  • 市场製约因素
    • 神经康復设备的高成本
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按产品类型
    • 神经机器人设备
    • 可穿戴设备
    • 无创刺激器
    • 脑机接口
  • 最终用户
    • 医院/诊所
    • 失智症护理中心
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Hocoma AG
    • Bionik Labs
    • Abbott Laboratories（St. Jude Medical Inc）
    • Ectron Ltd
    • MagVenture A/S
    • Helius Medical Technologies
    • Ekso Bionics
    • Rehabtronics Inc
    • Rehab-Robotics Company Limited
    • Eodyne Systems S.L.
    • Neofect
    • Neuro Rehab VR
    • Reha Technology AG
    • ReWalk Robotics Ltd.

第7章 市场机会与今后动向

简介目录
Product Code: 67835

The neurorehabilitation devices market is expected to register a CAGR of 13.7% during the forecast period (2022-2027).

COVID-19 has had a significant impact on the growth of the neurorehabilitation market. For instance, according to the study titled "Tele-Neurorehabilitation During the COVID-19 Pandemic: Implications for Practice in Low- and Middle-Income Countries (LMICs)" published in October 2021, telerehabilitation had been perceived as a key innovation and an effective strategy to combat the pandemic situation and lower the worldwide handicap load. It also reported that the pandemic scenario presented an opportunity to optimize and scale-up health-related technology advancements to tackle the rising burden of neurological impairment in LMICs. Thus, COVID-19 had a pronounced impact on the growth of the market.

Neurorehabilitation devices help improve function, reduce symptoms, and improve the well-being of people with diseases such as trauma or nervous system disorders. As per the research study published in February 2020, titled "Ischemic stroke in young adults: a global perspective," about 11 million cases of ischemic stroke occur every year across the world, of which more than half occur in low- and middle-income countries. Ischemic stroke is a major cause of long-term disability and has a profound effect on the quality of life of patients and caregivers. Since neurorehabilitation devices can be used in nearly 40% of cases of ischemic stroke to improve neurological functions, thereby growing burden of ischemic stroke augments the market growth.

In addition, the rise in the aging population is also driving the growth of this market, as the elderly population is vulnerable to various neurological disabilities such as acute ischemic stroke, Alzheimer's disease, and Parkinson's disease, among others. For instance, according to the World Population Aging Highlight of 2020 published by the United Nations, the global geriatric population (people aged 65 years or more) was 727 million in 2020, and it is expected to reach 1.5 billion by the end of 2050. Thus, the growing global geriatric population is expected to create a need for more neurorehabilitation devices, thus significantly impacting the growth of the market studied.

In addition, approvals for neurorehabilitation devices by international regulatory agencies also contribute to the market growth over the forecast period. For instance, in April 2021, the United States Food and Drug Administration granted marketing approval for the IpsiHand Upper Extremity Rehabilitation System (IpsiHand System), a brain-computer-interface (BCI) device that assists in rehabilitation for stroke patients with upper extremity or hand, wrist, and arm disability.

Therefore, the rising prevalence of neurological disorders, the growing geriatric population, and technological advancements in neurorehabilitation devices are the key driving factors for the market's growth. However, the high cost of neurorehabilitation devices may hinder market growth over the forecast period.

Neurorehabilitation Devices Market Trends

Neuro-Robotic Devices Segment is Expected to Hold a Major Market Share in the Neurorehabilitation Devices Market

The neuro-robotic devices segment projects significant growth in the neurorehabilitation devices market. It is anticipated to show a similar trend over the forecast period owing to the increasing burden of neurological diseases, technological advancements in robotics, and its combination with neuroscience, coupled with the launch of newer products.

Neuro-robotic devices combined with neuroscience and rehabilitation are the new methods for treating neurological disorders, which provide different ways of treatment depending on the specific function to be restored. Robotic devices for neurorehabilitation can be divided into two main categories based on the different types of physical human-robot interactions, such as end-effector devices and exoskeletons.

The research studies performed to understand the effectiveness of the robotic approach in neurorehabilitation also contribute to the adoption of devices and thus drive the growth of the segment. For instance, the study titled "Robotic Technology in Pediatric Neurorehabilitation" in a Pilot Study of Human Factors in an Italian Pediatric Hospital, published in May 2020, stated that patients reported improved quality of life and satisfaction after using robotic neurorehabilitation treatment. It also reported that the parents of patients who received robotic therapy had slightly greater expectations and satisfaction than those receiving conventional therapy. The study also showed that the robotic neurorehabilitation approach resulted in a considerable improvement in patient and parent expectations. Thus, the high effectiveness of neurorobotic devices in different studies may lead to increased adoption of these devices, thereby driving the growth of the segment.

Additionally, the establishment of new robotic-assisted neurorehabilitation centers improved the accessibility to neuro-robotic devices and is thus expected to contribute to segment growth. For instance, in December 2021, Sakra World Hospital, one of the leading healthcare organizations, launched a world-class robotic-assisted neuro-rehabilitation center in Karnataka, India.

Thus, the rising prevalence of neurological disorders, benefits associated with neuro-robotic devices, the establishment of robotic-assisted neurorehabilitation centers, and technological advancements are the key driving factors in the neuro-robotic devices segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global neurorehabilitation devices market due to growing incidences of stroke, Alzheimer's, and Parkinson's disease, growing geriatric population, and technological advancements in neurorehabilitation devices in this region.

According to the Centers for Disease Control and Prevention's May 2022 update, about 795,000 people experience a new or recurrent type of stroke every year. As per the epidemiology data, approximately 87% of strokes in the United States are ischemic. The rise in ischemic stroke will lead to increased neurorehabilitation device adoption in this region, thereby driving the growth of this market in North America.

Rising initiatives from the key players to increase awareness and growing adoption of neurorehabilitation are further expected to drive the growth of this market in the United States during the forecast period. For instance, in September 2021, Evolution Devices launched its EvoWalk Platform pilot program for the rehabilitation of walking for those living with neurologically based partial walking paralysis. The company's approach combines remote physical therapy (PT) with its EvoWalk smart stimulation device to help patients avoid falls and get instinctual movement back.

In addition, in December 2021, the Nebraska Chapter of the Fraternal Order of Eagles ("F.O.E."), an international non-profit community organization, purchased two EksoNR devices on behalf of local Nebraska inpatient rehabilitation facilities. Therefore, the rising adoption of these neurorehabilitation devices also drives the market growth.

Furthermore, increasing awareness regarding the benefits of neurorehabilitation devices and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Neurorehabilitation Devices Market Competitor Analysis

The neurorehabilitation devices market is consolidated and consists of a few major players. In terms of market share, a few major players dominate the market. Some companies currently dominating the market are Hocoma AG, Bionik Labs, St. Jude Medical Inc. (Abbott Laboratories), Electron Ltd, MagVenture A/S, Helius Medical Technologies, Ekso Bionics, Rehabtronics Inc., and Rehab-Robotics Company Limited.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Neurological Disorders
    • 4.2.2 Technological Advancements in Neurorehabilitation Devices
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Neurorehabilitation Devices
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Neuro-Robotic Devices
    • 5.1.2 Wearable Devices
    • 5.1.3 Non-Invasive Stimulators
    • 5.1.4 Brain-Computer Interface
  • 5.2 By End-User
    • 5.2.1 Hospitals/Clinics
    • 5.2.2 Cognitive Care Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Hocoma AG
    • 6.1.2 Bionik Labs
    • 6.1.3 Abbott Laboratories (St. Jude Medical Inc)
    • 6.1.4 Ectron Ltd
    • 6.1.5 MagVenture A/S
    • 6.1.6 Helius Medical Technologies
    • 6.1.7 Ekso Bionics
    • 6.1.8 Rehabtronics Inc
    • 6.1.9 Rehab-Robotics Company Limited
    • 6.1.10 Eodyne Systems S.L.
    • 6.1.11 Neofect
    • 6.1.12 Neuro Rehab VR
    • 6.1.13 Reha Technology AG
    • 6.1.14 ReWalk Robotics Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS